Cardiac Biomarker Diagnostic Kits Market By Product (Troponin Test Kits, CK-MB Test Kits, Myoglobin Test Kits, BNP Test Kit, C-reactive Protein, Other Biomarkers), By Disease Indication (Angina Pectoris, Myocardial Infraction, Cardiac Heart Failure), By Testing (Laboratory Testing, Pont-of-care Testing) – Growth, Share, Opportunities & Competitive Analysis, 2019 -2027

Cardiac biomarker diagnostic kits market to exhibit dynamic growth during the forecast period.

The global cardiac biomarker diagnostic kits market is growing competently at a CAGR of 5.3%. Globally, the rising prevalence of chronic diseases, cardiac disorders, and numerous lifestyle diseases will drive market growth. In addition, significant factors such as the growing elderly population, increasing hospital admissions for cardiovascular diseases, and enhanced product penetration in developing nations are driving the global market. Furthermore, present clinical trials for identifying innovative cardiac biomarkers and public and private funding for improved R&D are also increasing the market growth worldwide. Globally, a gradual shift towards overall treatment along with diagnosis for various lifestyle and chronic diseases is one of the key factors driving the market’s overall growth.

Market Synopsis

Troponin test kits expected to register higher growth by the end of 2027.

The troponin diagnostic test kits are estimated to grow significantly during the forecast period, generate maximum revenue in 2018, and are estimated to dominate by 2027. Top manufacturers are receiving U.S. FDA clearance. Product penetration of this segment can be accredited to an increase in the demand for high sensitive troponin assay applications. E.g., Alere recently launched next-generation products such as Troponin I, Cardio2, and Cardio3. Furthermore, the prevalence of acute myocardial infarction (AMI) will boost the need for advanced diagnostic kits on a global scale. Additionally, a huge number of pipeline products and advancements in point-of-care (POC) cardiac testing will increase the market share of diagnostic kits during the forecast period.

Angina Pectoris segment to witness a significant CAGR.

The increasing prevalence of cardiovascular diseases and a growing number of the adult population with an increased incidence rate of stroke, diseases in the arteries, and other lifestyle diseases will upsurge the market demand for diagnostic kits. As per the statistics by American Heart Association, cardiovascular disease is the leading global cause of death, accounting for more than 17 Mn deaths per year globally, expected to grow to more than 23 million by 2030 worldwide. Additionally, more than 9 million people in the U.S are projected to experience angina pectoris every year, with more than 500,000 new cases of angina pectoris occurring annually. The increasing prevalence of these diseases and the new launch of products for various disease indications globally will further revenue growth during the forecast period. In 2014-2015, stroke and CVD accounted for around 14% of total health expenditures, more than any major diagnostic segment globally. The total direct and indirect costs were more than US$ 350 Bn.

Increased research and development with strong product pipelines in the developed regions

Major manufacturers such as Abbott, Roche, Danaher, and others are developing novel products with enhanced applications in the point of care and laboratory testing segment. Increasing demand for laboratory investigation for the identification and diagnostic testing of various cardiac diseases is driving market growth. In addition, novel diagnostic kit launch with higher compatibility, strategic collaborations, innovative technology assessment in emerging countries, and improved clinical outcomes in the field of overall cardiac testing globally will further spur revenue growth on a global scale. E.g., In March 2017, Fujirebio Europe (leader in IVD testing) launched Lumipulse G Myoglobin immunoassays and Lumipulse® G hs Troponin I for both LUMIPULSE G600II and G1200 platforms.

Key Industry Developments: 

• In Oct 2017, Abbott Laboratories completed its acquisition of Alere (leader in rapid point-of-care diagnostics), closing a deal first declared in Feb 2016.
• In September 2018, Celemics Inc. and Firalis S.A. launched the FiMICS® panel. Both declared a definitive agreement to commercialize an exclusive proprietary long non-coding RNA (lncRNA) panel.

Top Companies

• bioMerieux SA
• Danaher Corporation
• Guangzhou Wondfo Biotech Co., Ltd
• Siemens AG
• Abbott Laboratories
• Alere, Inc.
• LSI Medience Corporation
• Randox laboratories
• Ortho Clinical Diagnostics
• Hoffmann-La Roche AG
• Thermofisher Scientific
• Bio-Rad Laboratories
• Others

Historical & Forecast Period

This study report represents analysis for each segment from 2017 to 2027, considering 2018 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2019 to 2027.

Segmentation Product Type (2017–2027; US$ Mn)

• Troponin Test Kits
• CK-MB Test Kits
• Myoglobin Test Kits
• BNP Test Kit
• C-reactive Protein
• Other Biomarkers

 Disease Indication (2017–2027; US$ Mn)

• Angina Pectoris
• Myocardial Infraction (MI)
• Cardiac Heart Failure

 Testing Segment (2017–2027; US$ Mn)

• Laboratory Testing
• Pont-of-care Testing

 Geography Segment (2017–2027; US$ Mn)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Russia
  • Rest of Europe
• Asia-Pacific
  • India
  • China
  • Japan
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities to understand the cardiac biomarker diagnostic kits market better. In addition, the global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolio, and business strengths.

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global CBDK Market
2.2. Global CBDK Market, by Product Type, 2018 (US$ Mn)
2.3. Global CBDK Market, by Disease Indication, 2018 (US$ Mn)
2.4. Global CBDK Market, by Testing, 2018 (US$ Mn)
2.5. Global CBDK Market, by Geography, 2018 (US$ Mn)

3. Market Dynamics
3.1. Introduction
3.1.1. Global CBDK Market Value, 2017-2027, (US$ Mn)
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.3. Attractive Investment Proposition, by Geography, 2018
3.4. Market Positioning of Key Players, 2018
3.4.1. Major Strategies Adopted by Key Players

4. Global Cardiac Biomarker Diagnostic Kits (CBDK) Market, by Product Type , 2017-2027 (US$ Mn)
4.1. Overview
4.2. Troponin Test Kits
4.3. CK-MB Test Kits
4.4. Myoglobin Test Kits
4.5. BNP Test Kit
4.6. C-reactive Protein (hsCRP)
4.7. Other Biomarkers

5. Global Cardiac Biomarker Diagnostic Kits (CBDK) Market, by Disease Indication, 2017-2027 (US$ Mn)
5.1. Overview
5.2. Angina Pectoris
5.3. Myocardial Infraction (MI)
5.4. Cardiac Heart Failure

6. Global Cardiac Biomarker Diagnostic Kits (CBDK) Market, by Testing, 2017-2027 (US$ Mn)
6.1. Laboratory Testing
6.2. Point of Care Testing

7. North America Cardiac Biomarker Diagnostic Kits (CBDK) Market Analysis, 2017-2027 (US$ Mn)
7.1. Overview
7.1.1. North America CBDK Market Value and Growth, 2017-2027, (US$ Mn)
7.2. North America CBDK Market Value, By Product Type, 2017-2027 (US$ Mn)
7.2.1. Market Analysis
7.3. North America CBDK Market Value, By Disease Indication, 2017-2027 (US$ Mn)
7.3.1. Market Analysis
7.4. North America CBDK Market Value, By Testing, 2017-2027 (US$ Mn)
7.4.1. Market Analysis
7.5. North America CBDK Market Value, By Region/Country, 2017-2027 (US$ Mn)
7.5.1. Market Analysis
7.5.2. U.S.
7.5.3. Rest of North America

8. Europe Cardiac Biomarker Diagnostic Kits (CBDK) Market Analysis, 2017-2027 (US$ Mn)
8.1. Overview
8.1.1. Europe CBDK Market Value and Growth, 2017-2027, (US$ Mn)
8.2. Europe CBDK Market Value, By Product Type, 2017-2027 (US$ Mn)
8.2.1. Market Analysis
8.3. Europe CBDK Market Value, By Disease Indication, 2017-2027 (US$ Mn)
8.3.1. Market Analysis
8.4. Europe CBDK Market Value, By Testing, 2017-2027 (US$ Mn)
8.4.1. Market Analysis
8.5. Europe CBDK Market Value, By Region/Country, 2017-2027 (US$ Mn)
8.5.1. Market Analysis
8.5.2. U.K.
8.5.3. Germany
8.5.4. France
8.5.5. Italy
8.5.6. Rest of Europe

9. Asia Pacific Cardiac Biomarker Diagnostic Kits (CBDK) Market Analysis, 2017-2027 (US$ Mn)
9.1. Overview
9.1.1. Asia Pacific CBDK Market Value and Growth, 2017-2027, (US$ Mn)
9.2. Asia Pacific CBDK Market Value, By Product Type, 2017-2027 (US$ Mn)
9.2.1. Market Analysis
9.3. Asia Pacific CBDK Market Value, By Disease Indication, 2017-2027 (US$ Mn)
9.3.1. Market Analysis
9.4. Asia Pacific CBDK Market Value, By Testing, 2017-2027 (US$ Mn)
9.4.1. Market Analysis
9.5. Asia Pacific CBDK Market Value, By Region/Country, 2017-2027 (US$ Mn)
9.5.1. Market Analysis
9.5.2. Japan
9.5.3. China
9.5.4. India
9.5.5. Rest of Asia Pacific

10. Rest of the World Cardiac Biomarker Diagnostic Kits (CBDK) Market Analysis, 2017-2027 (US$ Mn)
10.1. Overview
10.1.1. Rest of the World CBDK Market Value and Growth, 2017-2027, (US$ Mn)
10.2. Rest of the World CBDK Market Value, By Product Type, 2017-2027 (US$ Mn)
10.2.1. Market Analysis
10.3. Rest of the World CBDK Market Value, By Disease Indication, 2017-2027 (US$ Mn)
10.3.1. Market Analysis
10.4. Rest of the World CBDK Market Value, By Testing, 2017-2027 (US$ Mn)
10.4.1. Market Analysis
10.5. Rest of the World CBDK Market Value, By Region, 2017-2027 (US$ Mn)
10.5.1. Market Analysis
10.5.2. Middle East & Africa
10.5.3. Latin America

11. Company Profiles
11.1. bioMerieux SA
11.2. Danaher Corporation
11.3. Guangzhou Wondfo Biotech Co., Ltd
11.4. Siemens AG
11.5. Abbott Laboratories
11.6. Alere, Inc.
11.7. LSI Medience Corporation
11.8. Randox laboratories
11.9. Ortho Clinical Diagnostics
11.10. Hoffmann-La Roche AG
11.11. Thermofisher Scientific
11.12. Bio-Rad Laboratories

List of Figures

FIG. 1 Global Cardiac Biomarker Diagnostic Kits (CBDK) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global CBDK Market Segmentation
FIG. 4 Global CBDK Market, by Product Type, 2018 (US$ Mn)
FIG. 5 Global CBDK Market, Disease Indication, 2018 (US$ Mn)
FIG. 6 Global CBDK Market, by Testing, 2018 (US$ Mn)
FIG. 7 Global CBDK Market, by Geography, 2018 (US$ Mn)
FIG. 8 Attractive Investment Proposition, by Geography, 2018
FIG. 9 Global Market Positioning of Key CBDK Market Manufacturers, 2018
FIG. 10 Global CBDK Market Value Share, by Product Type, 2018 & 2027 (Value %)
FIG. 11 Global Troponin Test Kits CBDK Market, 2017–2027 (US$ Mn)
FIG. 12 Global CK-MB Test Kits CBDK Market, 2017–2027 (US$ Mn)
FIG. 13 Global Myoglobin Test Kits Market, 2017–2027 (US$ Mn)
FIG. 14 Global BNP Test Kit CBDK Market, 2017–2027 (US$ Mn)
FIG. 15 Global C-reactive Protein (hsCRP) CBDK Market, 2017–2027 (US$ Mn)
FIG. 16 Global Other Biomarkers Market, 2017–2027 (US$ Mn)
FIG. 17 Global CBDK Market Value Share, Disease Indication, 2018 & 2027 (Value %)
FIG. 18 Global CBDK Market for Angina Pectoris, 2017–2027 (US$ Mn)
FIG. 19 Global CBDK Market for Myocardial Infraction (MI), 2017–2027 (US$ Mn)
FIG. 20 Global CBDK Market for Cardiac Heart Failure, 2017–2027 (US$ Mn)
FIG. 21 Global CBDK Market Value Share, by Testing, 2018 & 2027 (Value %)
FIG. 22 Global CBDK Market for Laboratory Testing, 2017–2027 (US$ Mn)
FIG. 23 Global CBDK Market for Pont-of-care Testing, 2017–2027 (US$ Mn)
FIG. 24 North America CBDK Market, 2017–2027 (US$ Mn)
FIG. 25 Europe CBDK Market, 2017–2027 (US$ Mn)
FIG. 26 Asia Pacific CBDK Market, 2017–2027 (US$ Mn)
FIG. 27 RoW CBDK Market, 2017–2027 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Cardiac Biomarker Diagnostic Kits (CBDK) Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 Global CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 5 Global CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 6 Global CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 7 Global CBDK Market, by Geography, 2017–2027 (US$ Mn)
TABLE 8 North America CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 9 North America CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 10 North America CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 11 North America CBDK Market, by Country, 2017–2027 (US$ Mn)
TABLE 12 Europe CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 13 Europe CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 14 Europe CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 15 Europe CBDK Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 16 Asia Pacific CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 17 Asia Pacific CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 18 Asia Pacific CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 19 Asia Pacific CBDK Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 20 Rest of the World CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 21 Rest of the World CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 22 Rest of the World CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 23 Rest of the World CBDK Market, by Region, 2017–2027 (US$ Mn)
TABLE 24 bioMerieux SA: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 Danaher Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 Guangzhou Wondfo Biotech Co., Ltd: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 27 Siemens AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 28 Abbott Laboratories: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 29 Alere, Inc..: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 30 LSI Medience Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 31 Randox laboratories: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 32 Ortho Clinical Diagnostics: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 33 Hoffmann-La Roche AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 34 Bio-Rad Laboratories: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 35 Thermofisher Scientific: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)